Loading...
•
Jun 30, 2021
Ampio Q2 2021 Earnings Report
Announced financial results for the second quarter ended June 30, 2021.
Key Takeaways
Ampio Pharmaceuticals reported a net loss of $3.556 million for the second quarter of 2021. The company's cash and cash equivalents totaled $20.5 million as of June 30, 2021, compared to $17.3 million on December 31, 2020.
Completed Phase I trial utilizing inhaled Ampion for COVID-19 patients with respiratory distress.
Initiated Phase II trials utilizing inhaled Ampion and intravenous (IV) Ampion for COVID-19 patients with respiratory distress.
Commenced enrollment for Phase II trials, expecting incremental increase as the inhaled Ampion Phase II study expands to India.
Exploring the first at-home inhalation treatment for long COVID patients in a Phase I study utilizing inhaled Ampion.
Ampio
Ampio
Forward Guidance
Ampio expects to have sufficient funds to finance its operations through Q4 2022.
Positive Outlook
- Cash and cash equivalents are expected to be sufficient.
- Access to external sources of liquidity is expected.
- Funding for research and development programs is expected.
- Funding for business operations is expected.
- Financial visibility through the fourth quarter of 2022.